Top 25 Pharmaceutical Products in 2015

to p25 drugs Igea Luca Dezzani

to p25 drugs Igea Luca Dezzani

The prescription drugs market includes a large number of formulation products that address a diverse array of therapeutic requirements. Prescription drugs have life-cycle that is distinguished by high sales revenues during the patent-protected period. The parent companies invest in sales and marketing of the products to maximize their return on investment on research and development. The sales usually rapidly taper-off after patent expiry, as the products are exposed to competition from generics and biosimilars.

The global prescription drugs market was estimated to be USD 1,114 billion in 2015. A list of top-25 prescription drugs products based on sales revenues was collated using the reported revenues of the parent companies. These 25 drugs are marketed by 19 companies, that are the leading players in the pharmaceutical industry. The combined revenues of the top-25 drugs in this market together accounted for close to 15% of the global sales revenues of prescription drugs in 2015. Furthermore, these 25 drugs were also had a remarkably narrow scope of treatment profiles. Most drugs in the list are primarily for the treatment and management of cancer, diabetes, inflammatory disorders, and HIV or HCV infections.

table

  1. Humira

Humira (adalimumab) is a biologic therapy product for multiple inflammatory conditions that is administered as a subcutaneous injection. It remained the best-selling prescription drug product in the world in 2015. Humira is manufactured by AbbVie Inc. (U.S.), and is recommended for the treatment and management of rheumatoid arthritis. The sales of Humira was USD 14,021 million in 2015 – a 12% increase over the sales of USD 12,543 million in 2014. The sales of Humira accounted for 61% of AbbVie’s revenues in 2015. The composition patent for this product will expire in December 2016 in the U.S. and October 2018 in Europe. This is likely to expose the company to substantial competition from biosimilars.

 

  1. Harvoni

Harvoni (ledipasvir, sofosbuvir) is an oral formulation from Gilead Sciences, Inc. (U.S.) for the treatment of HCV. It was the best-selling product for Gilead in 2015. The revenues from Harvoni were USD 13,864 million in 2015. The product had debuted with sales of USD 2,127 million in 2014. The patent for the product will expire in 2030, making it an important candidate in Gilead’s patent estates.

 

  1. Enbrel

Enbrel (etanercept) is indicated for the treatment of rheumatoid arthritis, psoriasis and other inflammatory conditions. The sales of Enbrel were USD9,027 million in 2015. It is marketed by Amgen Inc. (U.S.) in the U.S. and Pfizer Inc. (U.S.) in Europe. Pfizer has and co-promotion agreement with Takeda Pharmaceutical Company Ltd. (Japan). Takeda markets Enbrel in Japan. Though the product is already facing competition in Europe, the U.S. patent of the product will expire in August 2019. Remicade, Humira, and Stelara are its important competitor products in the U.S.

 

  1. Remicade

Remicade (infliximab) is and anti-TNF alpha monoclonal antibody that is indicated for the treatment of rheumatoid arthritis and other inflammatory disorders. The sales of the product stood at USD 8,957 million in 2015. The sales declined by 9 % between 2014 and 2015. The U.S. patent for the product will expire in September 2018, following which the product is expected to face substantial competition from biosimilars.

 

  1. Lantus

Lantus (insulin glargine injection) marketed by Sanofi S.A. (France) was the top-selling diabetes product in the world in 2015. It is administered as a once-daily subcutaneous injection for the treatment of adult patients with type 2 diabetes. The revenues from Lantus stood at USD 7,209 million in 2015. The U.S. patent for the product expired in August 2014.

 

  1. Avastin

Avastin (bevacizumab) is an angiogenesis inhibitor that is used for the treatment of cancer. It was the best-selling product for F. Hoffmann-La Roche AG (Switzerland) in 2015. The U.S. patent for the product will expire in 2019. Roche has been applying for FDA approvals for the use of Avastin for the treatment and management of multiple types of cancers. The revenues of the product increased from USD 6,629 million in 2014 to USD 6,905 million in 2015.

 

  1. Herceptin

Herceptin (trastuzumab) is a targeted therapy for HER2-positive metastatic breast and gastric cancers. It was another one of Roche’s best-selling cancer treatment products in 2015. The revenues for Herceptin stood at USD 6,754 million in 2015. The U.S. patent for the product is set to expire in 2019.

 

  1. Prevnar

Prevnar was the world’s top-selling vaccine product in 2015. The sales of the Pneumococcal vaccine stood at USD 6,245 million in 2015 – a 40% increase from revenues of USD 4,464 million in 2014. Prevnar was one of the best-selling product for Pfizer Inc. (U.S.) in 2015, and is expected to remain an important part of the company’s portfolio till its U.S. patent expiry in 2026.

 

  1. MabThera / Rituxan

Rituxan (rituximab) is an anti-CD20 monoclonal antibody that is used for the treatment of cancer. It was one of the top-three products for Roche in 2015. The revenues for this product were USD 5,827 million in 2015. However, sales of the product are expected to decline after the expiry of its U.S. patent in 2015.

 

  1. Revlimid

Revlimid (lenalidomide) was the best-selling product for Celgene Corporation (U.S.) in 2015. The revenues for the company from Revlimid increased by over 16%, from USD 4,980 million in 2014 to USD 5,801 million in 2015. The product is indicated for the treatment of multiple myloma. It’s U.S. patent is expected to expire in 2027, which makes it an extremely important product in the company’s portfolio.

 

  1. Crestor

Crestor (rosuvastatin calcium), is a prescription cholesterol medication that is indicated for the treatment and management of CVD. The U.S. patent for the product expired in January 2016. The sales of the product have steadily declined since 2013. The revenues of the product were USD 5,427 million in 2015 – an 8.20% decline from revenues of USD 5,912 million in 2014.

 

  1. Sovaldi

Sovaldi (sofosbuvir) is a nucleotide analog polymerase inhibitor. The once daily oral formulation is indicated for the treatment of HCV. It one of the highest-selling products for Gilead Sciences, Inc. (U.S.). The revenues of this product were USD 5,276 million in 2015. However, it experienced a 49% decrease in sales between 2014 and 2015. Sovaldi’s U.S. patent will expire in 2029, which makes it another important candidate in Gilead’s portfolio.

 

  1. Seretide / Advair

Advair (salmeterol, fluticasone propionate) is indicated for the treatment and management of asthma. Advair is the best-selling product for GlaxoSmithKline plc (U.K.). The product’s revenues stood at USD 5,228 million in 2015. However, its sales have steadily declined since 2013. The sales of the product declined by 13% between 2014 and 2015 and 20% between 2013 and 2014. The sales are expected to decline further after the U.S. patent expiry in 2016.

 

  1. Copaxone

Copaxone (glatiramer acetate) is a subcutaneous injection formulation for the treatment of multiple sclerosis. It was the best-selling product for Teva Pharmaceutical Industries Ltd. (Israel) in 2015. However, the sales of the product have declined since the expiry of U.S. patent in May 2014. The revenue of the product declined by 7%, from USD 5,575 million in 2014 to USD 5,213 million in 2015.

 

  1. Neulasta

Neulasta (pegfilgrastim) is a recombinant human granulocyte-colony stimulating factor (G-CSF) from Amgen Inc. (U.S.). It is used to decrease the incidence of infection during cancer treatment. The U.S. patent for the product expired in June 2015. The revenues of the product stood at USD 4,715 million in 2015.

 

  1. Gleevec / Glivec

Glivec (imatinib) is a tyrosine-kinase inhibitor that is used for the treatment of multiple cancers. It was the best-selling product for Novartis AG (Switzerland) in 2015. The revenues from the product were USD 4,658 million in 2015. However, the revenues of the product declined by 2% between 2014 and 2015. The U.S. patent of the product expired in July 2015 and it is facing substantial completion from generics in emerging market like Asia.

 

  1. Xarelto

Xarelto (rivaroxaban) is a prescription oral anticoagulant manufactured by Bayer AG (Germany). It is marketed by Janssen Pharmaceutica (a subsidiary of Johnson & Johnson) in the U.S. The revenues of the product have increased rapidly between 2013 and 2015. The revenues of the product increased by 29% between 2014 and 2015 and by 77% between 2013 and 2014. With the U.S. patent for the product set to expire in 2020, Xarelto will remain the most important product in Bayer’s portfolio.

 

  1. Januvia

Januvia (sitagliptin) is indicated for the management of type-2 diabetes. It was one of the best-selling drug product for Merck & Co. (U.S.) in 2015. It The product’s revenues were USD 3,864 million in 2015, a 2% decline from USD 3,931 million in 2014. However, with the U.S. patent set to expire in 2022, Januvia will continue to remain one of the most important candidates of Merck’s portfolio.

 

  1. Lyrica

Lyrica (pregabalin) is an anti-epileptic from Pfizer Inc. (U.S.). It was the best-selling and fastest-growing products for neurological disorders in 2015. Lyrica’s sales increased from USD 3,350 million in 2014 to USD 3,655 million in 2015, at a 9% annual growth rate. The company’s product patent for Lyrica is set to expire in 2018, which will very likely ensure high sales figures for the product till the end of that period.

 

  1. Lucentis

Lucentis (ranibizumab injection) is the only ophthalmology product in the list of top-25 drugs. The product is indicated for the treatment of macular degeneration. It had sales of USD 3,630 million in 2015. However, sales of the product had declined by 14% between 2014 and 2015.

 

  1. Truvada

Truvada (emtricitabine, tenofovir disoproxil fumarate) was one of the top-3 products for Gilead Sciences, Inc. (U.S.) in 2015. Furthermore, with the U.S. patent of the product set to expire in 2021, it’ll continue to remain and important candidate in the company’s portfolio. The product is a nucleoside analog reverse transcriptase inhibitor (NRTI) that is indicated for the treatment of HIV-1 infections. The product had sales of USD 3,459 million in 2015, a 4% increase from sales of USD 3,340 million in 2014.

 

  1. Symbicort

Symbicort (budesonide, formoterol) is used for the prevention of bronchospasm in patients suffering from asthma or COPD. Symbicort was one of the best-selling products for AstraZeneca plc (U.K.) in 2015. Furthermore, it is the company’s only product in this list, the patent of which has not expired as of April 2016. The product’s sales declined sharply from USD 3,801 million in 2014 to USD 3,394 million in 2015.

 

  1. Spiriva

Spiriva (tiotropium) is an inhalation spray from Boehringer Ingelheim GmbH (Germany). It was the best-selling product for the company in 2015. The U.S. patent of the product expired in 2012. The sales of the product have consistently declined since then. The sales of the product declined from USD 4,007 million in 2013, to USD 3,651 million in 2014, to approximately USD 3,201 million in 2015.

 

  1. Nexium

Nexium (esomeprazole) is a proton pump inhibitor that is indicated for the treatment and management gastroesophageal reflux disease. It was one of the top-three products for AstraZeneca plc (U.K.) in 2015. However, following the expiration of the U.S. patent of the product in February 2015, the sales of the product have declined sharply. The product’s sales decreased by 26% from USD 4,292 million in 2014 to USD 3,196 million in 2015.

 

  1. Atripla

Atripla (efavirenz, emtricitabine, tenofovir disoproxil fumarate) is a once-daily anti-HIV formulation from Gilead Sciences, Inc. (U.S.). It was one of the company’s top-five products in 2015. The revenues for the product were USD 3,134 million in 2015 – a 10% decline from the sales of USD 3,470 million in 2014. However, Gilead’s patent for the product is set to expire in 2021, which makes this an important candidate in the company’s patent estates.

 

References:

Advertisements

Nplate® Study in The Lancet Shows Substantial Increase in Durable Platelet Response Among Children with Immune Thrombocytopenia

Amgen Igea Luca Dezzani

amgen

April 19, 2016

Amgen has announced that The Lancet published results from a Phase 3 randomized, double-blind, placebo-controlled study of Nplate® (romiplostim) in children with symptomatic immune thrombocytopenia (ITP). According to the study, 52 percent of Nplate patients achieved a durable platelet response, compared with 10 percent of placebo-treated patients (p=0.002, odds ratio 9.1, 95 percent CI: 1.9, 43.2). Moreover, Nplate reduced rates of bleeding by more than 30 percent in children affected by blood disorder.

“Children with ITP are at risk for serious bleeding events due to low platelet counts, which can be very frightening for these children and their parents. The results of this study suggest that romiplostim could reduce the frequency and severity of bleeding events for children suffering from symptomatic ITP, thus providing them with another potential treatment option,” said Michael D. Tarantino, M.D., The Bleeding and Clotting Disorders Institute, professor of Pediatrics and Medicine, University of Illinois College of Medicine-Peoria, Peoria, Illinois.

Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, said: “Nplate helps bone marrow produce more platelets, which in turn helps prevent bruising and bleeding which is important for children faced with this condition. These data are important in understanding how Nplate may play a role in helping children manage this disease. We will work with regulatory authorities towards an approval for Nplate for pediatric patients.”

 

Pfizer Announces Positive Top-Line Results for the Clinical Trial of IBRANCE®

Pfizer Igea Luca Dezzani

pfizer_rgb_pos_canvassed[1]

April 19, 2016

Pfizer Inc. has announced positive top-line results from the Phase 3 PALOMA-2 trial for IBRANCE®, an oral, first-in-class inhibitor of cyclin-dependent kinases (CDKs) 4 and 6. The study demonstrated an improvement in progression-free survival (PFS) for the combination of IBRANCE plus letrozole compared with letrozole plus placebo in post-menopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) advanced or metastatic breast cancer who had not received previous systemic treatment for their advanced disease.

This PALOMA-2 trial offers positive evidence for IBRANCE with letrozole in the first-line setting, which was first studied in the Phase 2 PALOMA-1 trial. These data will support additional planned global regulatory submissions and a request for conversion of the accelerated approval for IBRANCE to regular approval in the United States. Detailed safety and efficacy results from PALOMA-2 will be submitted for presentation at the 2016 Annual Meeting of American Society of Clinical Oncology (ASCO).

“PALOMA-2 represents the third randomized study to demonstrate the benefit of IBRANCE when added to hormonal therapy in the management of women with ER+, HER2- advanced breast cancer. IBRANCE remains the only CDK 4/6 inhibitor with Phase 3 data in this disease. These results provide confirmatory evidence for PALOMA-1 and will be used to support regulatory submissions around the world, including a request for conversion of IBRANCE from accelerated to full approval in the United States. We look forward to sharing the detailed results of PALOMA-2 with the oncology community and advancing our discussions with regulatory authorities,” said Dr. Mace Rothenberg, MD, chief medical officer, Pfizer Oncology & senior vice president, Global Product Development, Oncology.

 

Study Reveals that Opdivo from Bristol-Myers extends survival in head and neck cancer

Bristol-Myers

Apr 19, 2016

According to data from a late-stage study, the cancer immunotherapy drug of Bristol-Myers Squibb, Opdivo, assisted advanced head and neck cancer patients with a dismal prognosis live longer than other standard treatments.

Treatment with Opdivo led to a 30 percent reduction in risk of death, where median overall survival was 7.5 months in the 361-patient trial. This was better compared with 5.1 months for those who received any of three commonly used treatments chosen by researchers.

Some patients taking that type of immunotherapy experience far more durable responses, despite the fact that a median survival difference of less than three months may not sound like much. 36 percent of Opdivo patients were still alive after one year, compared with 16.6 percent of those who received either docetaxel, methotrexate, or Eli Lilly’s Erbitux, as reported by the researchers.

The results from this study paves the way for another approval for Opdivo, which is now approved in the treatment of advanced melanoma, kidney cancer, and non-small cell lung cancer.

Dr. Maura Gillison, the study’s lead investigator who presented the data at the American Association of Cancer Research meeting in New Orleans, said in an interview: “The most important thing is the difference in the proportion of patients who survived to a year. In a disease that was uniformly rapidly fatal, we’re seeing a subset of the population clearly benefiting.”

Pharmaceutical Sales Representatives – How to Stand Out in the Crowd?

Pharma Sales Rep Igea Luca Dezzani

Personality traits, Skills, Qualification & Challenges of a Great Pharma Sales Rep

Pharmaceutical sales representatives (pharma sales reps) are the sales people working for pharmaceutical companies, their primary job is to provide doctors information about latest changes in medical science.  They also serve as the best tool to persuade doctors and prescribers to prescribe their medicines to patients. There are so many people who want to get into pharmaceutical sales field because of its prestigious job nature. “A pharmaceutical sales representative sells a technologically advanced product to highly intelligent physicians in a very professional environment,” says Pat Riley, a pharmaceutical sales recruiter. And it’s popular because of stability, excellent benefits, better income, the potential for growth and the fact that pharmaceutical sales field is a recession-proof career.

Personality traits

  1. Confident and persistent
  2. Self-motivated and goal oriented
  3. Professional imagePharma sales rep
  4. Organized and polished
  5. Ambitious and persuasive
  6. Smart, ethical and positive
  7. Self-starter, energetic and problem-solver

Skills

  1. Excellent communication skills
  2. Good listener
  3. Presentation skills
  4. Analytical and planning skills
  5. Teamwork and networking skills
  6. Market and business awareness
  7. Negotiation skills
  8. Good physical and mental stamina

Qualification

Although pharmaceutical sales career is open to all graduates but following subjects improve your scope in the field:

  1. Pharmacy or pharmaceuticals
  2. Medicine
  3. Nursing
  4. Life sciences
  5. Dentistry
  6. Other health sciences
  7. Marketing or business administration

It’s rare to find a job in pharmaceutical sales without a college degree except for those having successful sales record. Work experience in sales is very important because there are only a few companies that are willing to hire inexperienced graduates, most of the pharmaceutical companies seek experienced sales person with successful business to business sales record.

Challenges for pharmaceutical sales representative

  1. Competition in the field has never been greater, there are too many sales reps in the field. The challenge is, how to stand out in the crowd? Because if one cannot distinguish him from others, the doctor is not going to remember him and his product.
  2. The pharmaceutical industry is always dynamic and there’re a lot of changes taking place in the field, a sales rep might feel insecure and doubted.
  3. Less time with doctors is also an important and major challenge. Most of the sales representatives don’t get more than 2 minutes from doctors.
  4. Time management is another major challenge because most of the time is wasted in going office to office and waiting for the doctor.
  5. Creating a solid selling message and reaching out to a doctor is a major challenge for new sales reps in the field.
  6. Pharma sales rep face the biggest challenge of communication while co-promoting a product. While working with the team you need to understand what goals others are given by the managers.

These are the most common challenges that every pharmaceutical sales representative faces in the field. The only way to overcome these challenges and be successful in the field is to be confident, persuasive, know more about almost everything and get into intelligent discussions with the doctor.

Janssen Collaborates with TESARO, Inc., for Niraparib in Prostate Cancer

JAN

Apr 06, 2016

Janssen Biotech, Inc. has announced that it has entered a worldwide collaboration and license agreement with TESARO, Inc. for exclusive rights to the investigational compound niraparib in prostate cancer, which is an orally administered poly polymerase (PARP) inhibitor. Nirparib is currently in late-stage development for patients with ovarian cancer and metastatic breast cancer.

As per the terms of the collaboration arrangement and license agreement, Janssen will have global rights and be responsible for all commercialization activities and development for niraparib for use in prostate cancer, except in Japan. TESARO will maintain global development, commercial rights and manufacturing for all other indications.

“PARP inhibitors are an exciting, emerging class of medicines in prostate cancer, and we believe niraparib will perfectly complement our existing portfolio. Our team is eager to apply its prostate cancer expertise to niraparib, and enthusiastic about its potential to expand our impact on the lives of men with this disease,” said Peter F. Lebowitz, M.D., Ph.D., Oncology Therapeutic Area Head, Janssen Research & Development, LLC.

The proteins of PARP play a key survival role in DNA repair in cancer cells. By preventing PARP, certain defective cancer cells are not capable of repairing themselves, which leads toward cell death. Some men with prostate cancer have these defective cancer cells and may get benefits from using a PARP inhibitor, either alone, or in combination with other treatments.

Corvus Pharmaceuticals Announces Results of Preclinical Studies Demonstrating Positive Results with CPI-444, an Investigational Immuno-Oncology Therapy

corvus.png

April 19, 2016

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of new immuno-oncology therapies. It has recently announced results of three preclinical studies of the Company’s lead oral checkpoint inhibitor, CPI-444. The studies demonstrated that CPI-444, a potent and selective inhibitor of the adenosine A2A receptor, was effective in stimulating various immune cells that generated anti-tumor immunity, suppressed tumor growth, and delayed tumor progression in animal models of cancer. The data were presented in 2016 Annual Meeting of American Association for Cancer Research (AACR) in New Orleans.

Richard A. Miller, M.D., an oncologist and co-founder, president and chief executive officer of Corvus, said: “These preclinical studies demonstrate that CPI-444 enhances the immune response to various tumors in animal models of melanoma, breast and colon cancer. Enhancement of T-cell function was also corroborated with adoptively transferred T-cells and with tumor vaccines, indicating that this agent may have broad applications in immuno-oncology. These studies support our commitment to advancing the clinical development of CPI-444 as an immuno-oncology therapy for many types of cancer. Based on these study findings and others, we have begun enrolling patients in a Phase 1/1b clinical trial to evaluate the safety, tolerability and preliminary efficacy of CPI-444 as a single agent and in combination with an anti-PD-L1 in patients with solid tumors.”

Leica Biosystems Collaborates with Merrimack Pharmaceuticals for Developing a Heregulin Companion Diagnostic for Seribantumab

leica Me

Apr 14, 2016

Leica Biosystems and Merrimack Pharmaceuticals has announced a strategic partnership for developing companion diagnostic assays for identifying patients who might best respond to current and future oncology therapies developed by Merrimack. These assays will be designed using Advanced Cell Diagnostics’ (ACD’s) RNAscope technology and will be processed on the BOND clinical advanced staining systems of Leica Biosystems.

The initial focus of this partnership will be developing a companion diagnostic assay for Merrimack’s seribantumab, or MM-121, an investigational therapy. This Seribantumab is a fully human, monoclonal antibody that targets ErbB3, a cell surface receptor that is activated by the ligand heregulin (HRG). This ErbB3 signaling identifies a unique, more difficult to treat cancer phenotype characterized by increased tumor growth and increased resistance to targeted, anti-endocrine, and cytotoxic therapies. Seribantumab is being investigated primarily in combination settings for blocking HRG activated ErbB3 signaling so that the anti-tumor effect of the combination therapy partner can be enhanced.

“We are pleased to be working with Merrimack on cancer therapies with the BOND platform. The partnership utilizing RNAscope technology is an example of Leica Biosystems paving the way for in situ RNA detection in personalized medicine.  The ease of use and high quality staining delivered by BOND systems makes them ideal platforms on which to deploy these very informative tests,” said Matthias Weber MD, President of Leica Biosystems.

Novartis Partners with the International Red Cross to provide medicines to Syrian refugees

 

novartis red cross

Apr 06, 2016

Novartis makes partnership with the International Committee of the Red Cross (ICRC) for improving treatment and care for Syrian refugees in Lebanon who are suffering from chronic diseases.

In Lebanon, half of the population does not have any type of health coverage, and the refugee crisis has placed an extra burden on medical facilities already struggling. These refugees face difficulties accessing medicines, diagnosis, and ongoing care. Novartis and the International Committee of the Red Cross (ICRC) are partnering to improve treatment and care for the most vulnerable people in Lebanon. The main goal is to establish a blueprint to improve diagnosis, treatment and follow-up of Lebanese and also the refugees who are suffering from chronic diseases.

Novartis has decided to provide medicines for diabetes and high blood pressure. These diseases together account for more than 50% of deaths in Lebanon every year. The medicines are being supplied through Novartis Access, a program focusing on availability and affordability of on- and off-patent medicines addressing key non-communicable diseases. These medicines are offered to public-sector healthcare providers and governments at a price of USD 1 per treatment per month in lower and lower-middle-income countries.

As said by Rodolfo Rossi, health coordinator at the ICRC in Lebanon: “Non-communicable diseases are on the rise, not only in the Middle East but worldwide. This will give the ICRC the opportunity to receive drugs for non-communicable diseases at a very preferential price, allowing us to include more patients.”

 

Pfizer Collaborates with IBM to Transform Parkinson’s Disease Care

 

Pfizer IBM (1)

April 7, 2016

Pfizer Inc. and IBM have announced a first-of-its-kind research collaboration for developing state-of-the-art remote monitoring solutions in order to transform how clinicians deliver care to patients suffering from Parkinson’s disease. This experimental approach will depend on a system of mobile devices, sensors, and machine learning for providing real-time, around-the-clock disease symptom information to researchers and clinicians. The eventual goal is to obtain a better understanding of a patient’s disease progression and medication response, which will help inform treatment decisions and clinical trial design, while also speeding up developing new therapeutic options.

In particular, Parkinson’s disease needs ongoing adjustment to medication depending on the response of the patient and progression of the disease. This collaboration between IBM and Pfizer seeks to create a holistic view of a patient’s well-being by seeking to measure a variety of health indicators accurately, including dyskinesia, motor function, cognition, sleep and daily activities, like grooming, eating, and dressing. Insights from these data could help clinicians understand the effect of a patient’s medication as the disease progresses. This will also enable them to help optimize the patient’s treatment regimen as required. Researchers will also have the insights and real-world evidence needed to help accelerate potential new and better therapies using data generated through the system.

“We have an opportunity to potentially redefine how we think about patient outcomes and 24/7 monitoring, by combining Pfizer’s scientific, medical and regulatory expertise with IBM’s ability to integrate and interpret complex data in innovative ways. The key to our success will be to deliver a reliable, scalable system of measurement and analysis that would help inform our clinical programs across important areas of unmet medical need, potentially accelerating the drug development and regulatory approval processes and helping us to get better therapies to patients, faster,” said Mikael Dolsten, M.D., Ph.D., President of Pfizer Worldwide Research and Development.